Supplementary Information

Smart Surface Coating of Drug Nanoparticles with Cross-linkable Polyethylene

Glycol for Bio-responsive and Highly Efficient Drug Delivery

Weijia Wei, a Xiujuan Zhang, *a Xianfeng Chenb, Mengjiao Zhou, a Ruirui Xu, a and Xiaohong

Zhang*a

Fig. S1 Synthetic route of PEG-Lys-LA₂




Fig. S2 The ¹H NMR of di-Boc-lysine-PEG⁵⁰⁰⁰





Fig. S3 The ^1H NMR of PEG 5000 -Lys-LA $_2$.



 $Fig. \ S4\ MALDI-TOF\ Mass\ Spectrometry\ of\ PEG-NH_2\ and\ PEG-Lys-(Lys-LA_2)_2.$




Fig. S5 UV-vis absorption spectra of NCL-PEG $_{\rm B}$ and CL-PEG $_{\rm B}$.




Fig. S6 DLS size analysis of bare DOX NPs, DOX-NCLPEG $_{\!B}$ NPs and DOX-CLPEG $_{\!B}$ NPs.




Fig. S7 .a) The evolution of the sizes of different NPs over a period of 3 days. b) The release profiles of DOX from DOX-C18PMH-PEG NPs, DOX-NCLPEG_A NPs and DOX-CLPEG_A NPs. c) The release profiles of DOX-CLPEG_A NPs in the presence of different concentrations of DTT in PBS. d) The release profiles of DOX-NCLPEG_A NPs and DOX-CLPEG_A NPs. For the DOX-CLPEG_A NPs, the release was in PBS for the first 5 h. After 5 h, 10 mM DTT was added to the solution.




Fig. S8 The blood circulation curve of DOX-C18PMH-PEG NPs, DOX-NCLPEG_A NPs and DOX-CLPEG_A NPs, which was obtained through recording the fluorescence intensities of DOX in the blood at various times after drug administration. The unit is the percentage of the injected dose per gram tissue (% ID g⁻¹).




Fig. S9 Cell viabilities of HeLa cell lines after being incubated with NCL-PEGB and CL-PEGB for 72 h.




Fig. S10 a and b) Cell viabilities of HeLa cell lines after being incubated with DOX·HCl, DOX-NCLPEG_B NPs and DOX-CLPEG_B NPs for 24 and 48 h, respectively.




Fig. S11 Biodistribution of a) DOX-NCLPE G_A NPs and b) DOX-CLPE G_A NPs in major organs and tumor tissues at different times after drug administration.




Fig. S12 Biodistribution of a) DOX-NCLPEG_B NPs and b) DOX-CLPEG_B NPs in major organs and tumor tissues at different times after drug administration.